Liraglutide treatment tended to normalize the plasma inflammatory markers (for plasma IL-10 levels: Z = −0.319, p = 0.805 for 3xTg-AD + Lira vs. WT mice; Z = −1.286, p = 0.234 for 3xTg-AD + Lira vs. 3xTg-AD mice; for plasma IL-1β levels: Z = −2.00, p = 0.051 for 3xTg-AD + Lira vs. WT mice; Z = −1.143, p = 0.295 for 3xTg-AD + Lira vs. 3xTg-AD mice; Table 1). Here, IL10 is linked to Alzheimer disease.